Fusion Pharmaceuticals’ (FUSN) “Market Perform” Rating Reaffirmed at Raymond James

Raymond James reaffirmed their market perform rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSNFree Report) in a research report released on Tuesday, Benzinga reports.

FUSN has been the subject of a number of other reports. Bloom Burton reissued a buy rating on shares of Fusion Pharmaceuticals in a research note on Friday, January 5th. Royal Bank of Canada raised their price objective on Fusion Pharmaceuticals from $12.00 to $16.00 and gave the company an outperform rating in a research note on Monday, March 4th. William Blair downgraded Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday. Brookline Capital Management downgraded Fusion Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. Finally, Oppenheimer raised their price objective on Fusion Pharmaceuticals from $13.00 to $15.00 and gave the company an outperform rating in a research note on Friday, January 5th. Twelve research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $20.25.

View Our Latest Analysis on Fusion Pharmaceuticals

Fusion Pharmaceuticals Stock Up 0.2 %

Fusion Pharmaceuticals stock opened at $21.24 on Tuesday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -14.44 and a beta of -0.85. The stock has a 50 day moving average of $11.50 and a two-hundred day moving average of $7.11. Fusion Pharmaceuticals has a twelve month low of $2.31 and a twelve month high of $21.30. The company has a current ratio of 11.63, a quick ratio of 11.63 and a debt-to-equity ratio of 0.18.

Institutional Investors Weigh In On Fusion Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $7,154,000. Goldman Sachs Group Inc. acquired a new stake in Fusion Pharmaceuticals during the 4th quarter valued at $145,000. Chartwell Investment Partners LLC acquired a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $480,000. Pier Capital LLC acquired a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $2,663,000. Finally, Weiss Multi Strategy Advisers LLC acquired a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $1,656,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

Fusion Pharmaceuticals Company Profile

(Get Free Report)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

See Also

Analyst Recommendations for Fusion Pharmaceuticals (NASDAQ:FUSN)

Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.